Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
FLUOROURACIL AGILA; FLUOROURACIL ALPHAPHARM; FLUOROURACIL MYLAN (Alphapharm Pty Ltd)
Product name
FLUOROURACIL AGILA; FLUOROURACIL ALPHAPHARM; FLUOROURACIL MYLAN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
254 (255 working days)
Active ingredients
fluorouracil
Registration type
New generic medicine
Indication
FLUOROURACIL AGILA; FLUOROURACIL ALPHAPHARM; FLUOROURACIL MYLAN (solution for injection) is indicated alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.
Fluorouracil should only be used when other proven measures have failed or are considered impractical.